Evidence map›Paper›PMID 25501681›Full record

ArticlePloS one2014

Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk.

Outi Vaarala, Arja Vuorela, Markku Partinen, Marc Baumann, Tobias L Freitag, Seppo Meri, Päivi Saavalainen, Matti Jauhiainen, Rabah Soliymani, Turkka Kirjavainen and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Human genetics of responses to vaccines.Clinical and experimental immunology · 2025
    Review
  7. Review
  8. Role of Placental Glucose Transporters in Determining Fetal Growth.Reproductive sciences (Thousand Oaks, Calif.) · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Update on Influenza Vaccines: Needs and Progress.The journal of allergy and clinical immunology. In practice · 2021
    Article
  14. Observational
  15. Article
  16. Vaccines for COVID-19.Clinical and experimental immunology · 2020
    Review
  17. Article
  18. Article
  19. Review
  20. No evidence of autoimmunity to human OXJournal of translational autoimmunity · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 1 country.

Outi VaaralaDepartment of Vaccinations and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland.
Arja VuorelaDepartment of Vaccinations and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland.
Markku PartinenHelsinki Sleep Clinic, Vitalmed Research Centre Helsinki and Haartman Institute, University of Helsinki, Helsinki, Finland.
Marc BaumannMeilahti Clinical Proteomics Core Facility, Institute of Biomedicine/Biochemistry and Developmental Biology, and NeuroMed Research Program, University of Helsinki, Helsinki, Finland.
Tobias L FreitagDepartment of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland and Research Program Unit, Immunobiology, University of Helsinki, Helsinki, Finland.
Seppo MeriDepartment of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland and Research Program Unit, Immunobiology, University of Helsinki, Helsinki, Finland.
Päivi SaavalainenDepartment of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland and Research Program Unit, Immunobiology, University of Helsinki, Helsinki, Finland.
Matti JauhiainenNational Institute for Health and Welfare, Public Health Genomics Research Unit, Biomedicum, Helsinki, Finland.
Rabah SoliymaniMeilahti Clinical Proteomics Core Facility, Institute of Biomedicine/Biochemistry and Developmental Biology, and NeuroMed Research Program, University of Helsinki, Helsinki, Finland.
Turkka KirjavainenDepartment of Pediatrics, Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
Päivi OlsenDepartment of Child Neurology, Oulu University Hospital, Oulu, Finland.
Outi Saarenpää-HeikkiläDepartment of Pediatrics, Tampere University Hospital, Tampere, Finland.
Juha RouvinenDepartment of Chemistry and Biocenter Kuopio, University of Eastern Finland, Joensuu, Finland.
Merja RoivainenDepartment of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Helsinki, Finland.
Hanna NohynekDepartment of Vaccinations and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland.
Jukka JokinenDepartment of Vaccinations and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland.
Ilkka JulkunenDepartment of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Helsinki, Finland; Department of Virology, University of Turku, Turku, Finland.
Terhi KilpiDepartment of Vaccinations and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland.
Finnish Institute for Health and Welfare · FIUniversity of Helsinki · FIHelsinki University Hospital · FIOulu University Hospital · FITampere University Hospital · FIUniversity of Eastern Finland · FIUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNarcolepsy results from immune-mediated destruction of hypocretin secreting neurons in hypothalamus, however the triggers and disease mechanisms are poorly understood. Vaccine-attributable risk of narcolepsy reported so far with the AS03 adjuvanted H1N1 vaccination Pandemrix has been manifold compared to the AS03 adjuvanted Arepanrix, which contained differently produced H1N1 viral antigen preparation. Hence, antigenic differences and antibody response to these vaccines were investigated. METHODS AND

findingsIncreased circulating IgG-antibody levels to Pandemrix H1N1 antigen were found in 47 children with Pandemrix-associated narcolepsy when compared to 57 healthy children vaccinated with Pandemrix. H1N1 antigen of Arepanrix inhibited poorly these antibodies indicating antigenic difference between Arepanrix and Pandemrix. High-resolution gel electrophoresis quantitation and mass spectrometry identification analyses revealed higher amounts of structurally altered viral nucleoprotein (NP) in Pandemrix. Increased antibody levels to hemagglutinin (HA) and NP, particularly to detergent treated NP, was seen in narcolepsy. Higher levels of antibodies to NP were found in children with DQB1*06:02 risk allele and in DQB1*06:02 transgenic mice immunized with Pandemrix when compared to controls.

conclusionsThis work identified 1) higher amounts of structurally altered viral NP in Pandemrix than in Arepanrix, 2) detergent-induced antigenic changes of viral NP, that are recognized by antibodies from children with narcolepsy, and 3) increased antibody response to NP in association of DQB1*06:02 risk allele of narcolepsy. These findings provide a link between Pandemrix and narcolepsy. Although detailed mechanisms of Pandemrix in narcolepsy remain elusive, our results move the focus from adjuvant(s) onto the H1N1 viral proteins.

Indexed as

AdolescentAllelesAnimalsAntibody FormationAntigens, ViralChildChild, PreschoolHLA-DQ beta-ChainsHumansImmunoglobulin GInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesMice, Inbred NODNarcolepsyOrthomyxoviridae InfectionsAntigens, ViralarepanrixHLA-DQB1 antigenHLA-DQ beta-ChainsImmunoglobulin GInfluenza Vaccinespandemrix

Identifiers

PMID25501681
PMCPMC4266499
OpenAlexW2031302069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.